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ENCOMIUM FOR KAREN 
ROTHENBERG 
ELLEN WRIGHT CLAYTON, MD, JD 
Karen Rothenberg is an extraordinary scholar and leader who changed the 
course of my career.  In law school, I wrote my note for journal on reproductive 
genetic testing, which appeared in 1978. Then I went to medical school and did 
a residency in pediatrics. As a young assistant professor, I had given a few talks 
about genetics and law but was still trying to find my way as an investigator and 
scholar.   
That all changed when Karen and Elizabeth Thomson invited me to give a 
talk on legal and regulatory issues at an NIH conference on Reproductive Genetic 
Testing: Its Impact on Women in November, 1991.  The conferees consisted of 
an all-star cast of leading women scholars from a variety of areas including 
philosophy, history, disability rights, sociology, anthropology, psychology, law, 
and obstetrics.1  The conference was both exhilarating and exhausting because it 
made clear the excitement, the challenge, and the necessity of working across 
disciplines to understand issues in their full complexity in order to work toward 
solutions; lessons that have shaped my own work ever since.   
This conference also epitomized the essential characteristics of Karen’s 
scholarship – her passion for addressing women’s issues, her commitment to 
understanding from many perspectives what is really at stake, and her insistence 
on wrestling issues to the ground – no superficial work allowed. I turn first to an 
example from her work on genetics, our point of first contact.  When Jeff 
Struewing at the National Institutes of Health demonstrated that Ashkenazi Jews 
had a higher prevalence of specific variants in BRCA1 and BRCA2 that created 
an intermediate risk of cancer,2 Karen went to work.  She worried the results of 
Struewing’s research would stigmatize a recognized and at times disfavored 
group.3 Her analysis informed later discussions of how to prevent group harm, a 
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 1. The participants were Abby Lippman, Ruth Schwartz Cohen, Deborah Kaplan, Mary Mahowald, 
Ruth Faden. Patricia A. King, R. Alta Charo, Elena A. Gates, Nancy Anne Press, Carole H. Browner, 
Rayna Rapp, Laurie Nsiah-Jefferson, Barbara Katz Rothman, and Rita Beck Black. 
 2. J. P. Struewing, et al., The Risk of Cancer Associated with Specific Mutations of BRCA1 and 
BRCA2 Among Ashkenazi Jews, 336 NEW ENGLAND J. MED. 1401 (1997). 
 3. K. H. Rothenberg, Breast Cancer, the Genetic “Quick Fix,” and the Jewish community. Ethical, 
Legal, and Social Challenges, 7 HEALTH MATRIX CLEVEL. 97 (1997); K. H. Rothenberg & A. B. Rutkin, 
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gnarly and still unresolved dilemma.4 Noting that individuals from whom the 
tissue samples had been obtained had not given consent for the use of these 
specimens, Karen helped to coordinate a survey of Jews about their views about 
the use of stored tissue for this type of research. This survey also covered their 
views on the acceptability of using different sources of tissues and about whether 
consent should be required.5 The investigators found that while the respondents 
were generally highly supportive of research, they wanted to provide written 
consent, particularly if the samples were collected in a clinical rather than a 
research setting. 
Karen is also a zealous advocate in the very best sense of the word.  After 
Struewing’s article appeared, she wrote an editorial that appeared in multiple 
newspapers6 arguing that women with these variants should not lose their 
insurance.7  She became deeply involved in the National Action Plan for Breast 
Cancer, a powerful grass roots organization. Additionally, she became involved 
at the National Institutes of Health and addressed, often in leadership roles, such 
issues to develop strategies to prevent genetic discrimination for individuals with 
variants that increased the risk of developing cancer, to create tools to obtain 
meaningful informed consent for research, and to govern the use of biological 
specimens.  Her work laid the foundation for the passage of the Genetic 
Information Nondiscrimination Act8 as well as the ongoing debate about use of 
biological specimens for research, most recently instantiated in the changes to 
the Regulations for the Protection of Human Research Participants that are 
currently going into effect.9 
Karen’s concern for women was not limited to genetics.  Early in her career, 
she was a vigorous advocate for including women in clinical research, during a 
time when this surprisingly was a topic of debate.10  Previously, researchers had 
 
Toward a Framework of Mutualism: the Jewish Community in Genetics Research, 1 COMMUNITY GENET. 
148 (1998). 
 4. K. M. Meagher, et al., Precisely Where Are We Going? Charting the New Terrain of Precision 
Prevention, 18 ANNU. REV. GENOMICS HU M. GENET. 369 (2017). 
 5. M. D. Schwartz, et al., Consent to the Use of Stored DNA for Genetics Research: a Survey of 
Attitudes in the Jewish Population, 98 AM. J. MED. GENET. 336 (2001). 
 6. K. Rothenberg, Miracles of genetics can bear heavy cost Participants in tests sometimes lose 
privacy and health insurance, BALTIMORE SUN July 20, 1997, accessed at 
https://www.baltimoresun.com/news/bs-xpm-1997-07-20-1997201005-story.html. 
 7. K. L. Hudson, et al., Genetic Discrimination and Health Insurance: An Urgent Need for Reform, 
270 SCIENCE 391 (1995); K. H. Rothenberg, Genetic Discrimination and Health Insurance: A Call for 
Legislative Action, 52 J. AM. MED. WOMENS ASSOC. 43 (1997). 
 8. Genetic Information Nondiscrimination Act of 2008, 42 USC §§ 2000ff et. seq., (2008). 
 9. Department of Homeland Security et al., Federal Policy for the Protection of Human Subjects, 
82 FED. REG. 7149 (2017). 
 10. Karen H Rothenberg, Gender Matters: Implications for Clinical Research and Women’s Health 
Care, 32 HOUS. L. REV. 1201(1995); Karen H Rothenberg, The Institute of Medicine’s Report on Women 
and Health Research: Implications for IRBs and the Research Community, 18 IRB: ETHICS & HUMAN 
RESEARCH 1 (1996); Eugene G Hayunga, et al., Women of Childbearing Potential in Clinical Research: 
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usually studied only men because women’s hormonal cycles and potential to 
become pregnant presented too many complications. Her advocacy carried the 
day, and although progress has been made, parity has not yet been achieved,11 
particularly for pregnant or “potentially pregnable” women.12 Karen was also 
deeply concerned about the HIV/AIDS epidemic, focusing both on the 
obligations of health care providers13 and also the impact of this disease on 
women, pointing out their greatly increased risk of domestic violence.14 
This discussion represents only part of her scholarly and policy impact.  
Over the course of Karen’s career, she has written and spoken extensively about 
the right to die, medical decision-making for children, research ethics, and access 
to health care.  For the last several years, she has explored in great depth the 
potential value of using drama to reveal new perspectives on the complexities of 
advances in genomics,15 ultimately publishing her book, The Drama of DNA:  
Narrative Genomics16, with Lynn Wein Bush. Illustrating the power and wisdom 
of this endeavor, Jules Odendahl-James, an artist-scholar wrote in his book 
review “Rothenberg and Bush’s narrative . . . scenarios move across time, across 
professional and personal networks, from the research study to the clinical trial 
to the medical case. . . . [demonstrating that e]thical and empathetic 
considerations are not a barrier to cutting-edge research; they are actually key 
elements to superior, successful medical science.”17  What an important lesson. 
What makes Professor Rothenberg’s accomplishments all the more 
remarkable is that she achieved them while creating a leading health law program 
from scratch at the University of Maryland, then stepping in as dean of the 
school, and ultimately advising the leadership of the National Human Genome 
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 11. Louise Pilote & Valeria Raparelli, Participation of Women in Clinical Trials: Not Yet Time to 
Rest on Our Laurels∗  (Elsevier  2018). 
 12. Rieke van der Graaf, et al., Fair Inclusion of Pregnant Women in Clinical Trials: An Integrated 
Scientific and Ethical Approach, 19 TRIALS 78 (2018). 
 13. Karen H Rothenberg, The AIDS Project: Creating a Public Health Policy—Rights and 
Obligations of Health Care Workers, 48 MD. L. REV. 93 (1989). 
 14. Karen H Rothenberg & Stephen J Paskey, The Risk of Domestic Violence and Women with HIV 
Infection: Implications for Partner Notification, Public Policy, and the Law, 85 AM. J. OF PUB. HEALTH 
1569 (1995); Richard L North & Karen H Rothenberg, Partner Notification and the Threat of Domestic 
Violence Against Women with HIV Infection, THE NEW ENGLAND J. OF MED. 1569 (1993); Karen H 
Rothenberg & Richard L North, The Duty to Warn Dilemma and Women with AIDS: Redefining the 
Foreseeable Victim, 2 CT. HEALTH SCI. & L. 90 (1991). 
 15. Karen H Rothenberg & Lynn W Bush, Genes and Plays: Bringing ELSI Issues to Life, 14 
GENETICS IN MED. 274 (2012); Karen H. Rothenberg, From Eugenics to the ‘New’ Genetics: “The Play’s 
the Thing,” 79 FORDHAM L. REV. 407 (2010). 
 16. KAREN H ROTHENBERG & LYNN WEIN BUSH, THE DRAMA OF DNA: NARRATIVE GENOMICS 
(Oxford University Press, USA. 2014). 
 17. Jules Odendahl-James, Book Review, AM. J. BIOETHICS, Dec. 2016, at W17 (reviewing 
ROTHENBERG & BUSH, supra note 16). 
  
158 JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 22:155 
Research Institute for many years, all while doing an almost immeasurable 
amount of service.  And to top it off, she was, and is, an unstintingly generous 
friend and mentor, for which I am supremely grateful. 
 
